Publications by authors named "Eri Taguchi"

Claim this Profile
I
In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
Yumi Sasayama, Maki Hasegawa, Eri Taguchi, Kohei Kubota, Takeshi Kuboyama

J Control Release· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and evaluation of a novel antibody-photon absorber conjugate reveals the possibility of photoimmunotherapy-induced vascular occlusion during treatment .
Yuya Isoda, Wen Piao, Eri Taguchi, Junko Iwano, Shigeki Takaoka

Oncotarget· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.
Daisuke Shinmi, Eri Taguchi, Junko Iwano, Tsuyoshi Yamaguchi, Kazuhiro Masuda

Bioconjug Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
Eri Taguchi, Kazuhide Nakamura, Toru Miura, Masabumi Shibuya, Toshiyuki Isoe

Cancer Sci· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Kazuhide Nakamura, Eri Taguchi, Toru Miura, Atsushi Yamamoto, Kazumi Takahashi

Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window.
Naoki Matsunaga, Kazuhide Nakamura, Atsushi Yamamoto, Eri Taguchi, Hiromi Tsunoda

Mol Cancer Ther· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.
Kazuhide Nakamura, Atsushi Yamamoto, Masaru Kamishohara, Kazumi Takahashi, Eri Taguchi

Mol Cancer Ther· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukocyte behavior in angiogenic vessels is affected by tumor-derived nitric oxide.
Chika Miyoshi, Eri Taguchi, Norio Ohshima

Jpn J Physiol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis